Antibiotic therapy for pelvic inflammatory disease

Ricardo F. Savaris*, Daniele G. Fuhrich, Jackson Maissiat, Rui V. Duarte, Jonathan Ross

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    22 Citations (SciVal)
    Original languageEnglish
    Article numberCD010285
    JournalCochrane Database of Systematic Reviews
    Volume2020
    Issue number8
    DOIs
    Publication statusPublished (VoR) - 21 Aug 2020

    Funding

    Source of funding: supported by Grupo de Pesquisa e Pos-Graduacão Do Hospital de Clínicas de Porto Alegre under grant # 03/006. GenProbe (San Diego, CA) donated the kits to run the bacteriological analysis, and Pfizer (New York, NY) donated azithromycin to the Global Program to Eliminate Trachoma (Dr Schachter had a National Institutes of Health grant to do operational research on azithromycin treatment of trachoma, and the company donated the drug). The drug used in this study was obtained independently in Brazil, without Pfizer support. The other authors had no potential conflicts of interest to disclose. consultancy payments from Mycovia and GlaxoSmithKline and conference support from Janssen and American Society for Microbiology, has research grants pending from Gilead, Viiv and Pfizer, and owns stock options in AstraZeneca and GlaxoSmithKline. Source of funding: NIH Grant U19AI084024 Study funded by Bayer HealthCare AG, Leverkusen, Germany. 1 author (PJ) received travel grants and consulting fees from GlaxoSmithKline and Sanofi-Pasteur-MSD, and consulting fees from Bayer HealthCare. 2 authors (QL and ZL) declared no conflicts of interest. 1 author (PR) was an employee of Bayer Vital GmbH; 2 authors (PA and BH) were employees of Bayer Schering Pharma. Source of funding: supported in part by National Institutes of Health grants AI12192 and 1PO1 AI24768 and by Merck, Sharp & Dohme, Westpoint, PA. No conflicts of interest reported. Source of funding: supported in part by a grant from Ortho Pharmaceutical Corporation, Raritan, NJ. No conflicts of interest declared. Source of funding: financial assistance, in part, provided by Smith Kline & French Laboratories, Philadelphia, PA. No conflicts of interest reported. Source of funding: supported by grant from the Upjohn Co., Kalamazoo, MI. No conflicts of interest reported.

    Fingerprint

    Dive into the research topics of 'Antibiotic therapy for pelvic inflammatory disease'. Together they form a unique fingerprint.

    Cite this